Abstract
Standardization of Products Necessary to Drive Acceptance of Microarrays
as Diagnostic Tools
Manufacturers of DNA microarrays are seriously challenged to overcome
laboratory-to-laboratory and platform-to-platform inconsistencies. Result
variability can be linked to a variety of reasons including varying probe length
and labeling protocols. Manufacturers are spending considerable time and effort
in comparing their products with 'industry standards' that include quantitative
polymerase chain reaction and other microarray platforms. Standardization of
data is expected to be an essential part of microarrays becoming effective
diagnostic tools.
This Frost & Sullivan research service examines the World DNA Microarray
Markets and discusses the competitive factors in them. It segments the market
into commercial, self-printed, and software products, and breaks down total
revenues by the three major geographic locations - United States, Europe, and
Rest-of-World. Industry challenges, strategies, market trends and opportunities
are described in detail, and have been derived through extensive interviews with
market participants.
Gene Expression Analyses Being Increasingly Used for Clinical Trials
Gene expression products are quickly becoming integral tools for both
pre-clinical and clinical research. "Gene expression analysis provides a
snapshot of what is happening in a system at the molecular level," states
the analyst. This information is vital to understand the workings of the system
and the factors that change the system.
The utility of microarray technology in the diagnostics arena is beginning to
be explored. In diagnostics, microarray technology is expected to be crucial for
making decisions relating to therapeutics. Microarrays have been used in
research for almost a decade; however, it is their promise as a therapeutic tool
that is expected to drive the market.
Commercial Products to Drive Market Growth
World DNA microarray revenue was $596 million in 2003 and is expected to
reach $937 million by 2010, at a compound annual growth rate of 6.7 percent.
Market growth is expected to be derived from the substantial gains in the
commercial market and continued growth in the scanner market.